First patients test 'Switchable' Cancer-Fighting cells
NCT ID NCT06248086
Summary
This was the first-ever study in people of a new type of CAR-T cell therapy called ASP2802 for B-cell lymphoma that has come back or not responded to prior treatments. The main goal was to find a safe dose and understand how the body handles the treatment. The study was terminated early after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site AU61004
Sydney, 3065, Australia
Conditions
Explore the condition pages connected to this study.